Omalizumab — Membership Pricing

Other medications in Respiratory & Allergies

• Pirfenidone
• Prednisolone Systemic
• Roflumilast
• Tezepelumab
• Theophylline
• Beclomethasone
• Benralizumab
• Benzonatate

About Omalizumab

Omalizumab, often known by its brand name Xolair, is a vital biologic medication for managing severe allergic conditions. If you or a loved one relies on this advanced treatment, you know its importance—and its cost. At TheDrugClub, we're dedicated to helping our members access crucial medications like omalizumab more affordably, making relief more attainable.

Omalizumab, marketed as Xolair, is a specialized biologic medication designed to treat specific severe allergic conditions when other treatments haven't provided sufficient relief. It offers a targeted approach for individuals struggling with its debilitating effects.

What Omalizumab Treats

This medication is approved for several challenging conditions:

• Severe Allergic Asthma: For individuals aged 6 and older whose asthma is not well-controlled by inhaled corticosteroids.
• Chronic Idiopathic Urticaria (CIU) / Chronic Spontaneous Urticaria (CSU): For those aged 12 and older who continue to have chronic hives despite antihistamine treatment.
• Nasal Polyps: For adults aged 18 and older when other treatments have been ineffective.

By addressing the underlying allergic response, omalizumab can significantly improve quality of life for patients with these conditions.

How Omalizumab Works

Omalizumab is a monoclonal antibody. This means it's a lab-produced protein designed to mimic the antibodies your body naturally makes. Specifically, omalizumab targets and binds to immunoglobulin E (IgE), an antibody that plays a key role in allergic reactions. By binding to IgE, omalizumab prevents it from attaching to

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Omalizumab is approved for (FDA label)

XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods.

Source: Read the full FDA label on DailyMed. Label effective date: August 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Omalizumab (FDA label)

WARNING: ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis [see Dosage and Administration (2.6) , Warnings and Precautions (5.1) and Adverse Reactions (6.1 , 6.2) ] . WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred after the first dose of XOLAIR but also has occurred beyond 1 year after beginning treatment. Initiate XOLAIR therapy in a healthcare setting, closely observe patients for an appropriate period of time after XOLAIR administration and be prepared to manage anaphylaxis which can be life-threatening.

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Omalizumab (FDA label)

Injection: a clear to slightly opalescent and colorless to pale brownish-yellow solution available in the following: 75 mg/0.5 mL single-dose prefilled syringe with needle shield 75 mg/0.5 mL single-dose prefilled autoinjector 150 mg/mL single-dose prefilled syringe with needle shield 150 mg/mL single-dose prefilled autoinjector 300 mg/2 mL (150 mg/mL) single-dose prefilled syringe with needle shield 300 mg/2 mL single-dose prefilled autoinjector For injection: 150 mg white lyophilized powder in a single-dose vial for reconstitution Injection: 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL (150 mg/mL) solution in a single-dose prefilled syringe. ( 3 ) 75 mg/0.5 mL, 150 mg/mL and 300 mg/2 mL solution in a single-dose prefilled autoinjector. ( 3 ) For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Omalizumab (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Anaphylaxis [see Boxed Warning and Warnings and Precautions (5.1) ] Malignancies [see Warnings and Precautions (5.2) ] Asthma : The most common adverse reactions (≥ 1% of patients) in clinical studies with adult and adolescent patients ≥12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache.

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Omalizumab (FDA label)

XOLAIR is contraindicated in patients with severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR [see Warnings and Precautions (5.1) ] . Severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR ( 4 , 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Omalizumab (FDA label)

Anaphylaxis: Initiate XOLAIR therapy in a healthcare setting prepared to manage anaphylaxis which can be life-threatening and observe patients for an appropriate period of time after administration. ( 5.1 ) Malignancy: Malignancies have been observed in clinical studies. ( 5.2 ) Acute Asthma Symptoms: Do not use for the treatment of acute bronchospasm or status asthmaticus. ( 5.3 ) Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. ( 5.4 ) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy, especially upon reduction of oral corticosteroids. ( 5.5 ) Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and symptoms similar to serum sickness. ( 5.6 ) Potential Medication Error Related to Emergency Treatment of Anaphylaxis: XOLAIR should not be used for emergency treatment of allergic reactions, including anaphylaxis. ( 5.9 ) 5.1 Anaphylaxis Anaphylaxis has been reported to occur

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Omalizumab (FDA label)

No formal drug interaction studies have been performed with XOLAIR. In patients with asthma, CRSwNP, and IgE-mediated food allergy the concomitant use of XOLAIR and allergen immunotherapy has not been evaluated . In patients with CSU, the use of XOLAIR in combination with immunosuppressive therapies has not been studied. No formal drug interaction studies have been performed. ( 7 )

Source: FDA prescribing information (DailyMed). Set ID: 7f6a2191-adfb-48b9-9bfa-0d9920479f0d. SPL document ID: 48785e56-4828-4f55-88e1-eca2cb88299d. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.